Ernexa Therapeutics Inc.

ERNA
$4.53 (+ $0.32 + 7.60%)
Last updated: 2026-08-11 03:54 UTC
ERNA Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS1140824079
CUSIP114082407
Market Price4.53
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E Ratio0.02
EPS56.32
Market Cap$9.8M
Book Value0.46
Price to Book2.747
Beta6.72
52w High14.4
52w Low1.09
Next Earnings DateN/A

Ernexa Therapeutics Inc. trades under ticker ERNA on NASDAQ as a stock. Use this page to review stock price, share price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US1140824079, CUSIP 114082407. Also searched as Ernexa Therapeutics.

Related researchERNA stock priceERNA share price114082407Ernexa Therapeutics stockErnexa Therapeutics share price
About the Company
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Price History